Adjustments for Stock Splits Clause Example from Business Contracts

Sales Agreement, dated March 22, 2019, between Rockwell Medical, Inc. and Cantor Fitzgerald & Co (Filed With SEC on March 22, 2019)

Sales Agreement, dated April 8, 2022, between Rockwell Medical, Inc. and Cantor Fitzgerald & Co (Filed With SEC on April 11, 2022)

Controlled Equity Offering Sales Agreement, dated as of March 6, 2019, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on March 7, 2019)

Controlled Equity OfferingSM Sales Agreement, by and between KalVista and Cantor Fitzgerald dated March 29, 2019 (Filed With SEC on March 29, 2019)

Sales Agreement, dated May 17, 2019, by and between Onconova Therapeutics, Inc. and Roth Capital Partners, LLC (Filed With SEC on May 17, 2019)

Sales Agreement (Filed With SEC on June 6, 2019)

Sales Agreement (Filed With SEC on February 12, 2020)

Open Market Sales AgreementSM, dated as of April 5, 2019, by and between Ocular Therapeutix, Inc. and Jefferies LLC (Filed With SEC on April 5, 2019)

At Market Issuance Sales Agreement, dated April 3, 2019, by and between Heat Biologics, Inc. and B. Riley FBR, Inc (Filed With SEC on April 4, 2019)

Amended and Restated Sales Agreement, dated August 24, 2020, among Heat Biologics, Inc., B. Riley Securities, Inc. and Cantor Fitzgerald & Co (Filed With SEC on August 24, 2020)

Capital on DemandTM Sales Agreement, dated May 16, 2019, by and between BioPharmX Corporation and JonesTrading Institutional Services LLC (Filed With SEC on May 16, 2019)

At the Market Sales Agreement, dated July 2, 2019, by and among Paratek Pharmaceuticals, Inc., Jefferies LLC, and BTIG, LLC (Filed With SEC on July 2, 2019)

At-the-Market Sales Agreement, dated May 17, 2021, by and between Paratek Pharmaceuticals, Inc. and BTIG, LLC (Filed With SEC on May 17, 2021)

Controlled Equity OfferingSM Sales Agreement by and between TransEnterix, Inc. and Cantor Fitzgerald & Co., dated August 12, 2019 (Filed With SEC on August 12, 2019)

Controlled Equity OfferingSM Sales Agreement by and among Asensus Surgical, Inc. and Cantor Fitzgerald & Co., Robert W. Baird & Co. Incorporated and Oppenheimer & Co. Inc., dated... (Filed With SEC on May 19, 2021)

Controlled Equity OfferingSM Sales Agreement, dated as of November 14, 2019, by and between HTG Molecular Diagnostics, Inc. and Cantor Fitzgerald & Co (Filed With SEC on November 15, 2019)

Controlled Equity OfferingSM Amended and Restated Sales Agreement, dated as of November 12, 2019, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on November 12, 2019)

Amended and Restated Sales Agreement, dated March 18, 2020 by and among Acer Therapeutics Inc., Roth Capital Partners, LLC, and JonesTrading Institutional Services LLC (Filed With SEC on March 18, 2020)

Sales Agreement, dated November 9, 2018, by and between Acer Therapeutics Inc. and Roth Capital Partners, LLC (Filed With SEC on November 9, 2018)

Sales Agreement, by and between Forty Seven, Inc. and Cantor Fitzgerald & Co., dated January 10, 2020 (Filed With SEC on January 10, 2020)

Sales Agreement, dated July 20, 2020, between Torchlight Energy Resources, Inc. and Roth Capital Partners, LLC (Filed With SEC on July 20, 2020)

Sales Agreement, dated as of June 16, 2021, by and between Torchlight Energy Resources, Inc. and Roth Capital Partners, LLC (Filed With SEC on June 16, 2021)

Amended and Restated Sales Agreement, dated as of June 21, 2021, by and between Torchlight Energy Resources, Inc. and Roth Capital Partners, LLC (Filed With SEC on June 21, 2021)

Sales Agreement, dated April 17, 2020, between Blink Charging Co. and Roth Capital Partners, LLC (Filed With SEC on April 17, 2020)

Sales Agreement, dated September 2, 2022, between Blink Charging Co. and the Agents (Filed With SEC on September 2, 2022)

Controlled Equity OfferingSM Sales Agreement, dated as of April 24, 2020, by and between vTv Therapeutics Inc. and Cantor Fitzgerald & Co (Filed With SEC on April 24, 2020)

ADDVANTAGE TECHNOLOGIES GROUP, INC. Common Stock ($0.01 par value per share) Equity Distribution Agreement (Filed With SEC on April 24, 2020)

Sales Agreement, dated May 1, 2020, by and among Anavex Life Sciences Corp., Cantor Fitzgerald & Co. and SVB Leerink LLC (Filed With SEC on May 1, 2020)

Equity Sales Agreement, dated as of May 7, 2020, among Pfenex Inc., William Blair & Company, L.L.C., and H.C. Wainwright & Co., LLC (Filed With SEC on May 7, 2020)

Sales Agreement, dated as of March 15, 2018, between Pfenex Inc. and William Blair & Company, L.L.C (Filed With SEC on March 15, 2018)

Controlled Equity OfferingSM Sales Agreement, dated May 8, 2020, by and between Ocugen, Inc. and Cantor Fitzgerald & Co (Filed With SEC on May 8, 2020)

Controlled Equity OfferingSM Sales Agreement, dated June 12, 2020, by and between Ocugen, Inc. and Cantor Fitzgerald & Co (Filed With SEC on June 12, 2020)

At Market Issuance Sales Agreement, dated August 14, 2020, by and among Ocugen, Inc., Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc (Filed With SEC on August 17, 2020)

At Market Issuance Sales Agreement, dated June 10, 2022, by and among Ocugen, Inc., Cantor Fitzgerald & Co., Mizuho Securities USA LLC, H.C. Wainwright & Co., LLC, Roth Capital... (Filed With SEC on June 10, 2022)

Controlled Equity OfferingSM Sales Agreement, dated August 5, 2020, by and between EyePoint Pharmaceuticals, Inc. and Cantor Fitzgerald & Co (Filed With SEC on August 5, 2020)

Controlled Equity OfferingSM Sales Agreement, dated as of May 20, 2020, by and between Paramount Gold Nevada Corp., Cantor Fitzgerald & Co. and Canaccord Genuity LLC (Filed With SEC on May 20, 2020)

At-the-Market Sales Agreement, dated May 27, 2020, by and between CohBar, Inc. and Virtu Americas LLC (Filed With SEC on May 27, 2020)

Sales Agreement, dated June 19, 2020, by and between Creative Realities, Inc. and Roth Capital Partners, LLC (Filed With SEC on June 19, 2020)

Controlled Equity OfferingSM Sales Agreement, dated November 27, 2020, by and between TherapeuticsMD, Inc. and Cantor Fitzgerald & Co (Filed With SEC on November 27, 2020)

Controlled Equity OfferingSM Sales Agreement, dated December 31, 2020, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on December 31, 2020)

Capital on Demand Sales Agreement (the Agreement) with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (Filed With SEC on February 12, 2021)

Sales Agreement, dated as of February 22, 2021, by and between The Alkaline Water Company Inc. and Roth Capital Partners, LLC (Filed With SEC on February 23, 2021)

Sales Agreement by and between Ideanomics, Inc. and Roth Capital Partners, LLC, dated as of February 26, 2021 (Filed With SEC on March 1, 2021)

Controlled Equity Offering Sales Agreement by and between Ideanomics, Inc. and Cantor Fitzgerald & Co. dated as of August 12, 2021 (Filed With SEC on August 13, 2021)

Capital on Demand Sales Agreement, dated March 11, 2021 between Ocuphire Pharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on March 11, 2021)

Controlled Equity Offering Sales Agreement, dated March 11, 2021, by and between the Registrant and Cantor Fitzgerald & Co (Filed With SEC on March 11, 2021)

Sales Agreement dated March 30, 2021, between the Company and Cantor Fitzgerald & Co (Filed With SEC on March 30, 2021)

Controlled Equity OfferingSM Sales Agreement, dated May 12, 2021, by and between Biocept, Inc. and Cantor Fitzgerald & Co (Filed With SEC on May 13, 2021)

Sales Agreement, dated as of May 28, 2021, by and among Accelerate Diagnostics, Inc. and William Blair & Company, L.L.C (Filed With SEC on May 28, 2021)

Sales Agreement among AgEagle Aerial Systems In., Stifel, Nicolaus & Company, Incorporated and Raymond James & Associates, Inc (Filed With SEC on May 28, 2021)

Controlled Equity OfferingSM Sales Agreement, dated as of June 28, 2021, by and among Zosano Pharma Corporation and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (Filed With SEC on June 28, 2021)

Sales Agreement dated July 6, 2021, between SemiLEDs Corporation and Roth Capital Partners, LLC (Filed With SEC on July 6, 2021)

Controlled Equity Offering (Filed With SEC on July 2, 2021)

Sales Agreement, dated August 13, 2021, by and between fuboTV Inc., Evercore Group L.L.C., Needham & Company, LLC and Oppenheimer & Co. Inc (Filed With SEC on August 13, 2021)

Sales Agreement dated August 16, 2021, between Blonder Tongue Laboratories, Inc. and Roth Capital Partners, LLC (Filed With SEC on August 16, 2021)

Equity Sales Agreement, dated as of November 3, 2021, by and between Potbelly Corporation and William Blair & Company, L.L.C (Filed With SEC on November 4, 2021)

Sales Agreement, dated December 17, 2021, by and among ALX Oncology Holdings Inc., Cantor Fitzgerald & Co., and Credit Suisse Securities (USA) LLC (Filed With SEC on December 17, 2021)

At Market Offering Sales Agreement, dated January 14, 2022 by and between Global Self Storage, Inc. and B. Riley Securities, Inc (Filed With SEC on January 14, 2022)

At Market Issuance Sales Agreement dated February 14, 2022 by and between CareCloud, Inc. and B. Riley Securities, Inc (Filed With SEC on February 14, 2022)

Sales Agreement, dated as of December 17, 2021, by and between the Company and Roth Capital Partners, LLC (Filed With SEC on March 10, 2022)

Form of Equity Distribution Agreement (Filed With SEC on March 18, 2022)

Controlled Equity Offering Sales Agreement, dated April 12, 2022, by and between BioCardia, Inc. and Cantor Fitzgerald & Co (Filed With SEC on April 12, 2022)

Sales Agreement, dated as of April 14, 2022, by and between CareDx, Inc. and Jefferies LLC (Filed With SEC on April 15, 2022)

Sales Agreement dated May 4, 2022 between SiTime Corporation and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on May 4, 2022)

Sales Agreement, dated May 20, 2022, between the Company and Roth Capital Partners, LLC (Filed With SEC on May 20, 2022)

At the Market Offering Agreement, dated May 25, 2022 by and between Celsion Corporation and H.C. Wainwright & Co., LLC (Filed With SEC on May 25, 2022)

Capital on DemandTM Sales Agreement, dated December 4, 2018, between Celsion Corporation and JonesTrading Institutional Services LLC (Filed With SEC on December 5, 2018)

Siebert Financial Corp. Common Stock ($0.01 par value per share) Capital on Demand™Sales Agreement (Filed With SEC on May 27, 2022)

Sales Agreement, dated June 7, 2022, by and between the Company and Roth Capital Partners, LLC (Filed With SEC on June 9, 2022)

Controlled Equity Offering Sales AgreementSM, dated June 17, 2022, by and among NexImmune Inc., Cantor Fitzgerald & Co. and BTIG, LLC (Filed With SEC on June 17, 2022)

Sales Agreement, dated August 9, 2022, between Precigen, Inc. and Cantor Fitzgerald & Co (Filed With SEC on August 9, 2022)

Equity Distribution Agreement, dated August 18, 2022, by and between Aspen Group, Inc. and Northland Securities, Inc (Filed With SEC on August 18, 2022)

Controlled EquitySM Sales Agreement, dated August 24, 2022, by and among Rani Therapeutics Holdings, Inc., and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (Filed With SEC on August 25, 2022)

Controlled Equity OfferingSM Sales Agreement, dated September 26, 2022, by and between Volta Inc. and Cantor Fitzgerald & Co (Filed With SEC on September 26, 2022)

Sales Agreement, dated September 28, 2022, by and between Momentus Inc. and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on September 28, 2022)

Sales Agreement, dated November 3, 2022, by and between the Registrant and ThinkEquity LLC (Filed With SEC on November 3, 2022)

Sales Agreement, dated as of December 9, 2022, by and between the Company and Roth Capital Partners, LLC (Filed With SEC on December 9, 2022)

Capital on Demand Sales Agreement, dated December 21, 2022 between NeuroOne Medical Technologies Corporation. and JonesTrading Institutional Services LLC (Filed With SEC on December 22, 2022)

Controlled Equity OfferingSM Sales Agreement, dated as of December 23, 2022, by and among Cognition Therapeutics, Inc., Cantor Fitzgerald & Co. and B. Riley Securities, Inc (Filed With SEC on December 23, 2022)

Controlled Equity Offering Sales AgreementSM, dated January 6, 2023, among the Company, Cantor Fitzgerald & Co. and BTIG, LLC (Filed With SEC on January 6, 2023)

Sales Agreement, dated January 31, 2023, by and between the Company and ThinkEquity LLC (Filed With SEC on January 31, 2023)

Sales Agreement, dated February 17, 2023, by and between the Registrant and ThinkEquity LLC (Filed With SEC on February 17, 2023)

Controlled Equity OfferingSM Sales Agreement, dated February 24, 2023, by and between Sanara MedTech Inc. and Cantor Fitzgerald & Co (Filed With SEC on February 24, 2023)

Sales Agreement, dated November 2, 2018, between OncoSec Medical Incorporated and Cantor Fitzgerald & Co (Filed With SEC on November 2, 2018)

Controlled Equity OfferingSM Sales Agreement, dated December 20, 2018, by and between Orgenesis Inc. and Cantor Fitzgerald & Co (Filed With SEC on December 20, 2018)

Controlled Equity OfferingSM Sales Agreement, dated December 7, 2018, by and between Sophiris Bio Inc. and Cantor Fitzgerald & Co (Filed With SEC on December 7, 2018)

Sales Agreement, dated as of August 9, 2018, between Ardelyx, Inc. and Leerink Partners LLC (Filed With SEC on August 10, 2018)

Capital on DemandTM Sales Agreement, dated August 10, 2018, by and between Standard Diversified Inc. and JonesTrading Institutional Services LLC (Filed With SEC on August 10, 2018)

Controlled Equity OfferingSM Sales Agreement, dated March 12, 2018, by and between NewLink Genetics Corporation and Cantor Fitzgerald & Co (Filed With SEC on March 13, 2018)

Controlled Equity OfferingSM Sales Agreement, dated February 6, 2018, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on February 6, 2018)

Sales Agreement, dated February 6, 2018, by and between the Company and B. Riley FBR, Inc (Filed With SEC on February 6, 2018)

Sales Agreement, dated February 27, 2018, by and between DPW Holdings, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on February 27, 2018)

Controlled Equity OfferingSM Sales Agreement, by and between MannKind and Cantor Fitzgerald & Co., dated February 27, 2018 (Filed With SEC on February 27, 2018)

MANITEX INTERNATIONAL, INC. Shares of Common Stock (no parvalue per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on January 23, 2017)

TETRAPHASE PHARMACEUTICALS, INC. Up to $40,000,000 Shares of CommonStock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on January 17, 2017)

Orexigen Therapeutics, Inc. Shares of Common Stock (par value$0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on March 30, 2017)